Wei Kong-Kong, Jiang Lei, Wei Yao-Yao, Wang Yu-Feng, Qian Xuan-Kun, Dai Qiang, Guan Quan-Lin
The First Clinical Medical College of Lanzhou University, Lanzhou, 730000, China.
Tumour Biol. 2014 Sep;35(9):8721-31. doi: 10.1007/s13277-014-2128-1. Epub 2014 May 29.
Numerous studies examined the association between excision repair complementation group 1 (ERCC1) expression and the prognosis of gastric cancer patients receiving platinum-based chemotherapy but yielded controversial results. We thus conducted a meta-analysis to quantitatively evaluate the prognostic value of ERCC1 expression in gastric cancer patients receiving platinum-based chemotherapy. A systematic literature search was performed to identify relevant studies in PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and WanFang Database up to December 17, 2013. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95 % confidence intervals (CIs) were estimated. Moreover, meta-regression analysis and subgroup analysis were conducted according to ethnicity, HR extraction, detection methods, survival analysis, and quality score. A total of 1,409 patients from 21 studies were subjected to final analysis. Positive/high ERCC1 expression was significantly associated with poorer overall survival (HR, 1.58; 95 % CI, 1.09-2.28), especially in Asians (HR, 1.81; 95 % CI, 1.20-2.73), and lower response rate (OR, 0.26; 95 % CI, 0.18-0.36), but not with clinicopathological features, such as gender (OR, 1.01; 95 % CI, 0.68-1.51), grade (OR, 0.66; 95 % CI, 0.43-1.01), and stage (OR, 1.05; 95 % CI, 0.58-1.90). This meta-analysis suggested that ERCC1 expression might be a useful biomarker to predict response and survival for gastric cancer patients receiving platinum-based chemotherapy, particularly in Asians.
众多研究探讨了切除修复互补组1（ERCC1）表达与接受铂类化疗的胃癌患者预后之间的关联，但结果存在争议。因此，我们进行了一项荟萃分析，以定量评估ERCC1表达在接受铂类化疗的胃癌患者中的预后价值。通过系统检索PubMed、科学网、Embase、考克兰图书馆、中国知网、中国生物医学文献数据库和万方数据库，查找截至2013年12月17日的相关研究。估计合并风险比（HRs）或比值比（ORs）及95%置信区间（CIs）。此外，根据种族、HR提取、检测方法、生存分析和质量评分进行了荟萃回归分析和亚组分析。最终分析纳入了来自21项研究的1409例患者。ERCC1表达阳性/高水平与较差的总生存期显著相关（HR，1.58；95%CI，1.09 - 2.28），尤其是在亚洲人中（HR，1.81；95%CI，1.20 - 2.73），且与较低的缓解率相关（OR，0.26；95%CI，0.18 - 0.36），但与性别（OR，1.01；95%CI，0.68 - 1.51）、分级（OR，0.66；95%CI，0.43 - 1.01）和分期（OR，1.05；95%CI，0.58 - 1.90）等临床病理特征无关。这项荟萃分析表明，ERCC1表达可能是预测接受铂类化疗的胃癌患者反应和生存的有用生物标志物，尤其是在亚洲人中。
